CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-06-27..
Gross margin
Overview →Financial period ending 2026-06-27; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-06-27. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | Gross Profit |
| Revenue | 4.00B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-27 | (m) | $4.00B | (m) | (m) |
| 2026-03-28 | (m) | $4.03B | (m) | (m) |
| 2025-12-27 | (m) | $4.02B | (m) | (m) |
| 2025-09-27 | (m) | $4.02B | (m) | (m) |
| 2025-06-28 | (m) | $4.03B | (m) | (m) |
| 2025-03-29 | (m) | $4.02B | (m) | (m) |
| 2024-12-28 | (m) | $4.05B | (m) | (m) |
| 2024-09-28 | (m) | $4.06B | (m) | (m) |
| 2024-06-29 | (m) | $4.08B | (m) | (m) |
| 2024-03-30 | (m) | $4.11B | (m) | (m) |
| 2023-12-30 | (m) | $4.13B | (m) | (m) |
| 2023-09-30 | (m) | $4.22B | (m) | (m) |
| 2023-07-01 | (m) | $4.18B | (m) | (m) |
| 2023-04-01 | (m) | $4.09B | (m) | (m) |
| 2022-12-31 | (m) | $3.98B | (m) | (m) |
| 2022-09-24 | (m) | $3.78B | (m) | (m) |
| 2022-06-25 | (m) | $3.69B | (m) | (m) |
| 2022-03-26 | (m) | $3.63B | (m) | (m) |
| 2021-12-25 | (m) | $3.54B | (m) | (m) |
| 2021-09-25 | (m) | $3.43B | (m) | (m) |
| 2021-06-26 | (m) | $3.27B | (m) | (m) |
| 2021-03-27 | (m) | $3.04B | (m) | (m) |
| 2020-12-26 | $1.07B | $2.92B | (m) | 36.72% |
| 2020-09-26 | (m) | $2.82B | (m) | (m) |
| 2020-06-27 | (m) | $2.75B | (m) | (m) |
| 2020-03-28 | (m) | $2.72B | (m) | (m) |
| 2019-12-28 | $958.31M | $2.62B | (m) | 36.56% |
| 2019-09-28 | (m) | $2.53B | (m) | (m) |
| 2019-06-29 | (m) | $2.45B | (m) | (m) |
| 2019-03-30 | (m) | $2.38B | (m) | (m) |
| 2018-12-29 | $840.07M | $2.27B | (m) | 37.07% |
| 2018-09-29 | (m) | $2.14B | (m) | (m) |
| 2018-06-30 | (m) | $2.02B | (m) | (m) |
| 2018-03-31 | (m) | $1.91B | (m) | (m) |
| 2017-12-30 | $702.31M | $1.86B | (m) | 37.81% |
| 2017-09-30 | (m) | $1.85B | (m) | (m) |
| 2017-07-01 | (m) | $1.81B | (m) | (m) |
| 2017-04-01 | (m) | $1.77B | (m) | (m) |
| 2016-12-31 | $646.67M | $1.68B | (m) | 38.46% |
| 2016-09-24 | (m) | $1.57B | (m) | (m) |
| 2016-06-25 | (m) | $1.49B | (m) | (m) |
| 2016-03-26 | (m) | $1.40B | (m) | (m) |
| 2015-12-26 | $531.09M | $1.36B | (m) | 38.96% |
| 2015-09-26 | (m) | $1.34B | (m) | (m) |
| 2015-06-27 | (m) | $1.32B | (m) | (m) |
| 2015-03-28 | (m) | $1.32B | (m) | (m) |
| 2014-12-27 | $472.66M | $1.30B | (m) | 36.42% |
| 2014-09-27 | (m) | $1.26B | (m) | (m) |
| 2014-06-28 | (m) | $1.22B | (m) | (m) |
| 2014-03-29 | (m) | $1.17B | (m) | (m) |
| 2013-12-28 | (m) | $1.17B | (m) | (m) |
| 2013-09-28 | (m) | $1.16B | (m) | (m) |
| 2013-06-29 | (m) | $1.14B | (m) | (m) |
| 2013-03-30 | (m) | $1.13B | (m) | (m) |
| 2012-12-29 | (m) | $1.13B | (m) | (m) |
| 2012-09-29 | (m) | $1.14B | (m) | (m) |
| 2012-06-30 | (m) | $1.14B | (m) | (m) |
| 2012-03-31 | (m) | $1.14B | (m) | (m) |
| 2011-12-31 | (m) | $1.14B | (m) | (m) |
| 2011-09-24 | (m) | $1.13B | (m) | (m) |
| 2011-06-25 | (m) | $1.13B | (m) | (m) |
| 2011-03-26 | (m) | $1.13B | (m) | (m) |
| 2010-12-25 | (m) | $1.13B | (m) | (m) |
| 2010-09-25 | (m) | (m) | (m) | (m) |
| 2010-06-26 | (m) | (m) | (m) | (m) |
| 2010-03-27 | (m) | (m) | (m) | (m) |
| 2009-12-26 | (m) | $1.17B | (m) | (m) |
| 2009-09-26 | (m) | (m) | (m) | (m) |
| 2009-06-27 | (m) | (m) | (m) | (m) |
| 2008-12-27 | (m) | $1.30B | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |